Skip to content

Clinical trials

Leukemia, Myeloid, Acute trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Country / region: United Kingdom Clear all

159 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20041
20056
20063
20073
20082
20097
20105
20118
20124
20137
20149
20158
201613
201712
20186
20196
202013
20217
202211
20232
20245
20258
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed80
Terminated29
Recruiting21
Active, not recruiting13
Unknown status13
Not yet recruiting1
Enrolling by invitation1
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AbbVie11
Janssen Research & Development, LLC8
Celgene7
Astellas Pharma Global Development, Inc.6
Novartis Pharmaceuticals6
Daiichi Sankyo5
Hoffmann-La Roche5
King's College Hospital NHS Trust5
University of Birmingham5
AstraZeneca4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute159
Myelodysplastic Syndromes59
Leukemia40
Precursor Cell Lymphoblastic Leukemia-Lymphoma28
Leukemia, Myelomonocytic, Chronic19
Neoplasms15
Hematologic Neoplasms14
Recurrence14
Lymphoma, Non-Hodgkin12
Multiple Myeloma11

Trials

Showing 1 to 25 of 159. Each trial links to its page on Pharma Observatory.

59 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.